FIELD: pharmaceuticals.
SUBSTANCE: polyethylene glycol-conjugated drug of Formula (I) or a pharmaceutically acceptable salt thereof, a method for its preparation, a pharmaceutical composition containing a polyethylene glycol-conjugated drug of Formula (I), and its use for the preparation of a drug for the cancer treatment.
(I)
EFFECT: intermediate for the preparation of a polyethylene glycol-conjugated drug of Formula (I) is also proposed.
15 cl, 15 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THIAZOLACTAM COMPOUNDS AS ERK INHIBITORS AND THEIR APPLICATIONS | 2020 |
|
RU2805569C1 |
| FXIa INHIBITORS, A METHOD OF THEIR PRODUCTION AND USE IN PHARMACEUTICALS | 2020 |
|
RU2802878C1 |
| SPIRO COMPOUNDS AS ERK INHIBITORS AND THEIR USE | 2020 |
|
RU2800042C1 |
| METHOD FOR OBTAINING AZETIDINONE COMPOUNDS AND DERIVATIVES OF AZETIDINONE COMPOUNDS | 2015 |
|
RU2650687C1 |
| FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
| CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | 2017 |
|
RU2722720C1 |
| QUININE COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR MEDICAL APPLICATION | 2014 |
|
RU2641285C2 |
| QUINAZOLINE DERIVATIVES | 2015 |
|
RU2704125C2 |
| PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | 2017 |
|
RU2711991C1 |
| PRODUCTION OF COMPOUNDS AND COMPOSITIONS FOR SUPPRESSION OF SHP2 ACTIVITY | 2019 |
|
RU2797951C2 |
